| Basics |
Actinium Pharmaceuticals, Inc
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's product portfolio includes Iomab-B and Actimab-A.
|
| IPO Date: |
January 1, 2003 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$47.11M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.15 | 3.48%
|
| Avg Daily Range (30 D): |
$0.04 | 2.63%
|
| Avg Daily Range (90 D): |
$0.04 | 2.49%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.03M |
| Avg Daily Volume (30 D): |
.18M |
| Avg Daily Volume (90 D): |
.17M |
| Trade Size |
| Avg Trade Size (Sh.): |
444 |
| Avg Trade Size (Sh.) (30 D): |
238 |
| Avg Trade Size (Sh.) (90 D): |
240 |
| Institutional Trades |
| Total Inst.Trades: |
47 |
| Avg Inst. Trade: |
$1.86M |
| Avg Inst. Trade (30 D): |
$2.2M |
| Avg Inst. Trade (90 D): |
$2.2M |
| Avg Inst. Trade Volume: |
.24M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.11M |
| Avg Closing Trade (30 D): |
$3.87M |
| Avg Closing Trade (90 D): |
$3.87M |
| Avg Closing Volume: |
431.92K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-1.11
|
$-.16
|
$-.22
|
|
Diluted EPS
|
$-1.11
|
$-.16
|
$-.22
|
|
Revenue
|
$ .09M
|
$ .09M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -34.6M
|
$ -5.13M
|
$ -6.88M
|
|
Operating Income / Loss
|
$ -37.34M
|
$ -5.69M
|
$ -7.5M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -5.75M
|
$ M
|
$ M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Aug 11, 2020:
1:30
|
|
|
|
